This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PPI-1019
Description: Apan specifically inhibits the aggregation of beta-amyloid and its associated nerve cell toxicity.
Deal Structure: Apan was developed by Praecis Pharmaceuticals until the company was aquired by GlaxoSmithKline in February 2007.
Pink Sheet One-stop patent filings
Additional information available to subscribers only: